Sangamo stock climbs 12% post-market on FDA update for ST-503

Shares of Sangamo Therapeutics ( NASDAQ: SGMO ) rose 12% in post-market trading Tuesday after the company announced the FDA had cleared it to begin clinical testing of its drug candidate ST-503 in the treatment of intractable pain due to idiopathic small fiber.